Suzlon’s outperformance was driven by the strong increase in order book and its improved balance sheet along with cash flows from operations. Suzlon’s order book is now at an all-time high, near the mark of 5 GW.
Marketbuzz Podcast: The Indian market is likely to start in green tracking global cues with a focus on IT stocks. Tune in to the podcast for more cues
UBS has initiated coverage on Zydus Lifesciences Ltd. and Dr Reddy’s Laboratories Ltd. with a ‘Sell’ recommendation, setting price targets of ₹850 and ₹5,700 per share, respectively, citing that the market is overestimating their core margins.
Goldman Sachs is anticipating Gland Pharma’s profitability to face headwinds. It has highlighted five factors as to why it believes so.
Nuvama Wealth Management Share Price | On Thursday, September 26, CNBC-TV18 reported, citing sources, that Edel Finance Company and Ecap Equities were to sell a combined 6.4% equity stake in Nuvama Wealth Management through block deals.
On Friday, market tech analysts Mitessh Thakkar and Shrikant Chouhan recommended these stocks for the short term.
Indian IT stocks are the top gainers on the Nifty 50 index today, with LTIMindtree leading with a surge of 3%, while Tech Mahindra, Infosys, and Wipro shares are trading with gains of over 2% each.
The Nifty 50 is currently trading at 21.5 times its one-year forward earnings whereas the KOSPI commands a valuation of 8.8 times.
Swiggy has a high attrition rate over the last three fiscals as highlighted in its DRHP. Read on to know more about the risk factors.
Post Content